nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.03.2011

Primary aldosteronism: A contrarian view

verfasst von: Norman M. Kaplan

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

This paper provides evidence that primary aldosteronism is likely much less common than is believed by the other authors of this collection. The basis for this contrarian view is simple: there is no way to know the true prevalence of PA because of the uncertain validity of all of the diagnostic procedures used to find and characterize this disease. Moreover, even if these uncertainties are overcome, the eventual treatment of most who have PA can be provided without the need for extensive testing and expensive treatment.

Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.PubMedCrossRef

Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–5.PubMedCrossRef

Gordon RD, Klemm SA, Stowasser M, et al. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? Curr Sci. 1993;11 Suppl 5:S310–1.

Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006;24:737–45.PubMedCrossRef

Kaplan NM, Victor RG. Chapter 11 primary aldosteronism. In Kaplan’s clinical hypertension, 10th ed. LWW, Philadelphia; 2010. p. 339–57.

Mulatero P, Bertello C, Verhovez A, et al. Differential diagnosis of primary aldosteronism subtypes. Curr Hypertens Rep. 2009;11:217–23.PubMedCrossRef

Sukor N, Gordon RD, Kim Y, et al. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009;94:2437–45.PubMedCrossRef

Schirpenbach C, Seiler L, Maser-Gluth C, et al. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem. 52:1749–55.

Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2009;94:3623–30.PubMedCrossRef

10.

Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892–6.PubMedCrossRef

11.

Bernini G, Moretti A, Orlandini C, et al. Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens. 2008;26:981–8.PubMedCrossRef

12.

Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. J Hypertens. 2003;21:2149–57.PubMedCrossRef

13.

Fommei E, Ghione S, Ripoli A, et al. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women. J Hum Hypertens. 2009;23:130–5.PubMedCrossRef

14.

Pizzolo F, Raffaelli R, Memmo A, et al. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J Hypertens. 2010;28:135–42.PubMedCrossRef

15.

Tanabe A, Naruse M, Takagi S, et al. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab. 2003;88:2489–94.PubMedCrossRef

16.

Rossi GP, Seccia TM, Palumbo G, et al. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension. 2010;55:83–9.PubMedCrossRef

17.

Kem DC, Weinberger MH, Mayes DM, et al. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med. 1971;128:380–6.PubMedCrossRef

18.

Rossi GP, Belfiore A, Bernini G, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens. 2007;25:1433–42.PubMedCrossRef

19.

Bravo EL. Primary aldosteronism: issues in diagnosis and management. Endocrinol Metab Clin NA. 1994;23:271–83.

20.

Young Jr WF. Primary aldosteronism: management issues. Ann NY Acad Sci. 2002;970:61–76.PubMedCrossRef

21.

Thibonnier M, Sassano P, Joseph A, et al. Diagnostic value of a single dose of captopril in renin- and aldosterone-dependent, surgically curable hypertension. Cardiovasc Rev Rep. 1982;3:1659–67.

22.

Wu V, Chang W, Liu K, et al. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. Am J Hypertens. 2009;22:821–7.PubMedCrossRef

23.

Mattsson C, Young Jr WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006;2:198–208.PubMedCrossRef

24.

Kampers MJE, Lenders JWM, Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329–37.

25.

Mulatero P, Bertello C, Sukor N, et al. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension. 2010;55:667–73.PubMedCrossRef

26.

Stewart PM, Allolio B. Adrenal vein sampling for primary aldosteronism: time for a reality check. Clin Endocrinol. 2010;72:146–8.CrossRef

27.

Young Jr WF. Clinical practice: the incidentally discovered adrenal mass. N Engl J Med. 2007;356:601–10.PubMedCrossRef

28.

Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro Hypertens. 2007;50:447–53.CrossRef

29.

Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–6.PubMedCrossRef

30.

Mackenzie IS, Brown MJ. Molecular and clinical investigations in patients with low-renin hypertension. Clin Exp Nephrol. 2009;13:1–8.PubMedCrossRef

31.

Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma Renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypentens. 2010;28:170–7.CrossRef

32.

de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147–52.PubMedCrossRef

33.

Born-Frontberg E, Reincke M, Rump LC, et al. Cardiovascular and comordidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s registry. J Clin Endocrinol Metab. 2009;94:1125–30.CrossRef

34.

Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80–5.PubMedCrossRef

Titel: Primary aldosteronism: A contrarian view
verfasst von: Norman M. Kaplan
Publikationsdatum: 01.03.2011
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2011
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-011-9160-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Diagnosis and treatment of primary aldosteronism

Primary aldosteronism, diagnosis and treatment in Japan

Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism

Treatment of primary aldosteronism: Where are we now?